Disruption of Synaptic Vesicle Trafficking in Alzheimer's and Parkinson's Disease: Mechanisms and Therapeutic Implication.
Mechanistic review focusing on how disruptions of the synaptic vesicle trafficking cycle—driven in PD by alpha-synuclein aggregation and LRRK2-Rab trafficking defects—contribute to presynaptic dysfunction and summarizes mechanism-oriented therapeutic strategies.
What the AI sees
Mechanistic review focusing on how disruptions of the synaptic vesicle trafficking cycle—driven in PD by alpha-synuclein aggregation and LRRK2-Rab trafficking defects—contribute to presynaptic dysfunction and summarizes mechanism-oriented therapeutic strategies.
Research significance
By organizing presynaptic pathology around the vesicle cycle and highlighting PD-relevant targets (α-synuclein, LRRK2/Rab) and intervention strategies, the review provides a useful, translationally-relevant framework to guide target selection and early-stage therapeutic development for Parkinson's…
Source abstract
Alzheimer's (AD) and Parkinson's disease (PD) are prominent neurodegenerative disorders characterized by early synaptic loss, which correlates more closely with clinical symptoms than neuronal death. This synaptic impairment is primarily driven by disruptions in synaptic vesicle (SV) trafficking, a critical process for maintaining synaptic integrity through a tightly regulated cycle involving clustering, docking-priming, Ca2+-triggered fusion, and endocytosis. In AD, amyloid-β (Aβ) oligomers interfere with SNARE-mediated fusion and endocytosis, while hyperphosphorylated tau obstructs vesicle mobility and docking, resulting in cumulative toxicity that aggravates SV defects. Conversely, in PD, α-synuclein (α-syn) aggregation alters vesicle clustering, membrane fusion, and recycling, and these effects are further influenced by Leucine-rich repeat kinase 2 (LRRK2)-Rab-related trafficking defects and the selective vulnerability of dopaminergic terminals. Different from previous reviews that address synaptic dysfunction in a broader manner, the present review is specifically organized around the SV trafficking cycle and compares both shared presynaptic endpoints and disease-specific upstream mechanisms in AD and PD. In addition, recent mechanism-oriented therapeutic strategies are summarized. This vesicle-cycle-centered perspective may provide a clearer framework for understanding presynaptic pathology and for guiding the development of earlier and more targeted interventions.